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Background. Chinese herbal products (CHPs) given as a therapy for symptom relief have gained widespread popularity among
womenwithbreastcancer.TheaimofthisstudywastoanalyzetheutilizationofCHPamongwomenwithbreastcancerinTaiwan.
Methods. The usage, frequency of services, and CHP prescribed for breast cancer among women with breast cancer were evaluated,
recruited from a randomly sampled cohort of 1,000,000 beneﬁciaries from the National Health Insurance Research Database. The
logisticregressionmethodwasemployedtoestimatetheoddsratios(ORs)forutilizationofCHP.Results.81.5percent(N = 2,236)
ofwomenwithbreastcancerutilizedtraditionalChinesemedicine(TCM)and18%ofthemsoughtTCMwiththeintentoftreating
their breast cancer. Jia-wei-xiao-yao-san (Augmented Rambling Powder) was the most frequently prescribed formula for treating
breast cancer. Among the top 10 most frequently prescribed CHP for treating breast cancer, seven contained dang qui (Angelica
sinensis-radix) and six contained ren shen (Panax ginseng-radix), which are reported to have potential beneﬁcial synergistic eﬀects
on breast cancer cells. Conclusion. CHP containing dang qui (Angelica sinensis-radix)o rr e ns h e n( Panax ginseng-radix)a r et h e
most frequently prescribed for breast cancer and their eﬀects should be taken into account by healthcare providers.
1.Introduction
Despite the lack of solid evidence supporting their therapeu-
tic beneﬁt, the reported incidence of use of complementary
and alternative medicines (CAMs) among women with
breast cancer ranges from 66.7 to 97% [1–3]. An increased
perception of breast cancer recurrence and of breast cancer-
related death [4] may be the reasons why patients use a
wide range of CAM including herbs, vitamins, homeopathic
remedies, and Chinese herbal products (CHPs) [5–8]. The
expectations of CAM use vary among individuals. Some just
hope to strengthen their immune system, some expect to
decrease the treatment-associated toxicity, and some want to
alleviate the cancer-derived symptoms [9]. However, there is
no compelling evidence supporting the eﬀectiveness of CAM
use in breast cancer patients [5, 10]. In view of such and
without further knowledge on how eﬀective CAM is, it is
not easy for oncologists or CAM practitioners to provide an
appropriate recommendation that can meet the expectations
of women with breast cancer.
Traditional Chinese medicine (TCM) has been growing
in popularity and has oﬀered an important alternative or
complement to health care in many countries. The most
common type of CAM used by Chinese women with breast
cancer is CHP [11]. Previous studies have disclosed the
potentialbeneﬁcialsynergisticeﬀectsoftheusageofdangqui
(Angelica sinensis-radix)[ 12–14]o rren shen (Panax ginseng-
radix)[ 15–17] among women with breast cancer. Although
a previous four-year survey [11] indicated that over 50% of
breast cancer patients considered CHP eﬀective in treating
cancer, the utilization of individual CHP has rarely been
reported. In Taiwan, CHPs have been an important part of
health care for hundreds of years and are fully reimbursed
under the current National Health Insurance (NHI) system.2 Evidence-Based Complementary and Alternative Medicine
Accordingly, the claims database provides a platform for
understanding the utilization of CHP prescribed by licensed
TCM doctors. The aim of our study is to analyze a random
sample of this comprehensive database and to determine
the CHP utilization patterns for women with newly diag-
nosed breast cancer in Taiwan. Results of this study may
provide valuable information for physicians, enabling them
to respond to patients’ use of CHP in an informed way and
strengthening the patient-physician relationship in breast
cancer care.
2.MaterialsandMethods
2.1. Data Resources and Study Sample. This study was con-
ducted after approval by the review board of the Committee
on Chinese Medicine and Pharmacy (CCMP), Department
of Health, Taiwan. It was designed as a population-based
study to analyze a sample of 1 million subjects selected at
random from the 22 million beneﬁciaries of the National
Health Insurance scheme of Taiwan and to determine the
prevalence of prescribed CHP in women with breast cancer
between January 1, 1997, and December 31, 2008. All data
were obtained from the National Health Insurance Research
Database (NHIRD), which included all the reimbursement
data of the NHI with identiﬁcation numbers of all individu-
als encrypted, transformed, and maintained by the National
Health Research Institutes of Taiwan [18]. The NHIRD
database contained patient’s gender and date of birth, all
recordsofclinicalvisitsandhospitalization,prescribeddrugs
and dosages, including CHP, and three major diagnoses
coded in the International Classiﬁcation of Diseases, Ninth
Revision, Clinical Modiﬁcation (ICD-9-CM) format [19].
The selection of study subjects from the random sam-
ple of one million individuals was performed as follows
(Figure 1). First, we excluded all male beneﬁciaries (n =
495,835) or those with missing information concerning
gender (n = 3). Second, female beneﬁciaries without breast
cancer (n = 500,809) were excluded. Third, the prevalent
cases of other cancers (n = 125) and breast cancer (n = 486)
diagnosed before the end of 1998 were also excluded to make
sure that all the subjects included were newly diagnosed with
invasive breast cancer and the diagnosis was veriﬁed by the
NHI registry of catastrophic illnesses during 1998–2008. All
patients who are registered to have a catastrophic illness are
exempted from all copayments. To be registered as such,
patients must have the diagnosis of invasive breast cancer
(ICD-9code174)validatedbytissuepathology.Finally,2,742
female subjects were included in the cohort.
2.2. Traditional Chinese Medicine. TCM treatments include
CHP,acupunctureandmanipulativetherapiesfortrauma,all
of which are reimbursed by the NHI of Taiwan. CHPs com-
posedofoneormoreherbs(formula)aremostwidelyadopt-
ed by patients in Taiwan [20]. To study the utilization of pre-
scribed CHP in the present study, we downloaded the detail-
ed herbal contents for all kinds of reimbursed CHP from
the website of the CCMP, including the name of each CHP,
the proportion of each constituent, the date and period of
approval as drug, the code, and the name of manufacturer.
For simplicity, all CHPs with the same CCMP standard for-
mulas are classiﬁed under the same categories, regardless of
slight variations among products of diﬀerent pharmaceutical
companies [21].
2.3. Study Variables. To determine the key independent
variables for the utilization of CHP among women with
breast cancer, we selected the demographic factors according
to previous studies [22]. Ages were categorized into seven
groups: ≤29, 30–39, 40–49, 50–59, 60–69, 70–79, and ≥ 80
years. Geographic areas of Taiwan were classiﬁed into the
following six regions: Taipei city, Kaohsiung city, Northern,
Central, Eastern, and Southern regions. We split the monthly
wageintofourlevels:NewTaiwanDollars(NT$)0,1–19,999,
20,000–39,999, and ≥40,000.
2.4. Statistical Analysis. Data analysis was performed by
descriptive statistics, including the prescription rates of CHP
users stratiﬁed by patient’s age, indications for the prescrip-
tion of CHP, and the most frequently prescribed herbal
formulas for treating breast cancer. Primary indications were
classiﬁed according to the ICD-9. The diagnoses were coded
according to the ICD-9 and grouped into diﬀerent broader
disease categories. For example, ICD-9 codes 460–519 were
classiﬁed as diseases of the respiratory system, codes 780–799
weregroupedassymptoms,signs,andill-deﬁnedconditions,
and codes 520–579 were classiﬁed as diseases of the digestive
system. Multiple logistic regression was conducted to evalu-
ate factors that correlated with CHP use. A signiﬁcance level
of α = 0.05 was selected. The statistical software SAS 9.13
was used for data management and analyses.
3. Results
The database of outpatient claims contained information on
2,742 women with breast cancer from 1999 to 2008. Among
them, 2,236 (81.5%) breast cancer patients used TCM
outpatient services. Most TCM users (95.8%) also received
cancer treatment (Table 1). The mean age of TCM nonusers
was signiﬁcantly higher than that of TCM users. There were
more TCM users than TCM nonusers with income level of
NT$ 1–19,999 or residing in Central and Southern Taiwan.
There was no signiﬁcant diﬀerence in cancer treatment
modalities between TCM users and non-TCM users.
Adjusted odds ratios (aORs) and 95% conﬁdence inter-
vals (95% CIs) obtained by multiple logistic regression are
summarized in Table 1. Compared with the age group of 30–
39 years (aOR = 1.00), there were no signiﬁcant diﬀerences
in ages between TCM users and TCM nonusers except those
aged 80 years and above who were more likely to be non-
TCM users. There was also no signiﬁcant diﬀerence or trend
among women in diﬀerent income groups.
Chinese herbal medicines were prescribed in 22,755
(76.8%) of visits made by women to TCM doctors, with
acupuncture and manipulative therapies for trauma pre-
scribed for the rest. Analysis of the major disease categories
for 2,236 TCM users (Table 2) showed that breast cancer was
themostcommonreasonforusingCHP(21.7%,n = 6,442),
followed by “symptoms, signs, and ill-deﬁned conditions”Evidence-Based Complementary and Alternative Medicine 3
Exclusion of prevalent cases
of breast cancer before the
end of 1998, N = 486
Exclusion of prevalent cases
of other cancers before the
end of 1998, N = 125
Exclusion of 495,835 men
and 3 patients with missing data
on gender
Cases of breast cancer,
N = 3,353
Cases of breast cancer,
N = 3,228
All women
N = 504,162
Exclusion of cases without
breast cancer, N = 500,809
New cases of breast cancer,
N = 2,742
TCM nonusers,
N = 506
TCM users,
N = 2,236
One-million random
sample of NHIRD
N = 1,000,000
Figure 1: Flowchart of recruitment of subjects from the 1-million random sample of the National Health Insurance Research Database
(NHIRD) from 1999 to 2008 in Taiwan.
(17.5%, n = 5,177), and “diseases of the respiratory system”
(11.0%, n = 3,253), as summarized in Table 2.
Details on the most frequently prescribed CHP for treat-
ing breast cancer by TCM doctors are provided in Table 3.
As can be seen, Jia-wei-xiao-yao-san (Augmented Rambling
Powder) is the most frequently prescribed CHP, followed by
Xiang-sha-liu-jun-zi-tang (Vladimiria and Amomum Combi-
nation)a n dGui-pi-tang (Ginseng and Longan Combination).
Among the top 10 most frequently prescribed CHPs, seven
containing dang qui (Angelica sinensis-radix) and six con-
taining ren shen (Panax ginseng-radix) of various doses were
identiﬁed.
Although over 81% (n = 2,236) of women with breast
cancer had used TCM and CHP as the major method of
treatment from 1999 to 2008, only about 18% (n = 466)
of them sought TCM with the intent of either treating
their breast cancer or relieving the treatment-related side
eﬀects. CHP was prescribed in addition to surgery, radiation
therapy, and/or chemotherapy and appeared to be used as
an adjunct to conventional treatments for cancer, rather
than as alternatives. The top three formulas most frequently
prescribed by TCM doctors for treating breast cancer were
Jia-wei-xiao-yao-san (Augmented Rambling Powder), Xiang-
sha-liu-jun-zi-tang (VladimiriaandAmomumCombination),
and Gui-pi-tang (Ginseng and Longan Combination).
4. Discussion
The increasing trend of TCM utilization among women with
breast cancer in Taiwan is in line with trends reported from
China[1].However,theprevalenceofCHPusetotreatbreast
cancer among Taiwanese women is far below the propor-
tions in other countries [2, 3, 6]. Previous studies reported
that approximately 43–80% of breast cancer patients used
CAM as part of the treatment for their breast cancer [1–
3, 6]. Possibly fear of cancer recurrence and cancer-related
death is motivation for women to use CAM therapies. The
diﬀerence in results between the present study and those
previously reported was probably due to the disparities in
deﬁnition of breast cancer treatment between patients and
licensed TCM doctors. Previous studies [1–3, 6]c o l l e c t e d
the information of breast cancer treatment via self-reported
questionnaire, which represented the patients’ own percep-
tion and expectation of the prescribed treatment. On the4 Evidence-Based Complementary and Alternative Medicine
Table 1: Demographic characteristics and results of multiple logistic regression showing the adjusted odds ratio (aOR) and 95% CI
(conﬁdence interval) of women with newly diagnosed breast cancer from the 1-million random sample of the National Health Insurance
Research Database (NHIRD) from 1999 to 2008 in Taiwan.
Characteristics TCMa nonusers TCM users aORb (95% CIc)
No. of cases 506 2,236
CHPd for breast cancer — 503
Age at diagnosis (years)
≤29 8 26 0.63 (0.26–1.52)
30–39 51 283 1
40–49 165 771 0.84 (0.59–1.19)
50–59 146 617 0.78 (0.54–1.11)
60–69 75 356 0.86 (0.57–1.28)
70–79 40 146 0.75 (0.46–1.22)
≥80 21 37 0.35 (0.18–0.68)
Insured salaries (NT$e/month)
0+ 120 416 1
1–19999 234 1178 1.24 (0.93–1.64)
20000–39999 96 432 1.02 (0.73–1.43)
>40000 56 210 0.96 (0.65–1.42)
Insured region
Taipei city 171 555 1
Kaohsiung city 34 148 1.33 (0.88–2.02)
Northern Taiwan 159 644 1.27 (0.98–1.63)
Middle Taiwan 49 380 2.66 (1.86–3.79)
Southern Taiwan 80 431 1.83 (1.33–2.52)
Eastern Taiwan 10 59 2.25 (0.98–5.14)
Cancer treatment modalities
No treatment 26 93 0.86 (0.49–1.51)
Surgery only 46 207 1
Chemotherapy only 7 29 0.98 (0.39–2.47)
Hormone therapy only 21 98 1.07 (0.60–1.91)
Surgery and chemotherapy 74 305 0.82 (0.54–1.25)
Surgery and hormone therapy 113 508 1.10 (0.74–1.63)
Surgery, chemotherapy, and hormone
therapy 193 885 1.00 (0.69–1.44)
Others 26 111 0.99 (0.60–1.63)
aTCM refers to traditional Chinese medicine; bOR refers to odds ratio; cCI refers to conﬁdence interval; dCHP refers to Chinese herbal products;e NT$ refers
to new Taiwan dollars, of which 1 US$ = 30NT$.
contrary, the perspective of TCM doctors concerning the
treatment prescribed must be in line with the requirement
of the NHI in Taiwan. They had to follow the standard diag-
noses using the ICD-9-CM [20] coding system when claim-
ing reimbursement, and women with breast cancer are
exempted from all copayments once TCM doctors coded
their diagnoses as ICD-9 code 174 (malignant neoplasm of
female breast) to the NHI bureau. Another possible explan-
ation is that the present study demonstrated only the uti-
lization of CHP, which is the modern form of Chinese
herbal remedies, of which a single herb and herbal formulas
are concentrated into granulated compounds and made
available like over-the-counter dietary supplements in the
United States [23]. Decoctions and Chinese herbal remedies
purchaseddirectlyfromTCMherbalpharmacies,whichwere
classiﬁed as Chinese herbal medications, were not included
in the present study. Although the present ﬁndings cannot
be generalized to the comprehensive usage of various types
of CAM, the present study using a random national-level
sample revealed the prevalence in use of CHP prescribed by
licensed TCM doctors for treating breast cancer.
Although TCM as a unique traditional therapy for
various ailments has been used in Taiwan for over hundreds
of years, more than 95% of CHP users continued to receive
standard breast cancer treatment during the 10-year study
period. Moreover, regardless of the experiences caused by
receiving diﬀerent types of moderately toxic cancer treat-
ments, the choice of major medical options among womenEvidence-Based Complementary and Alternative Medicine 5
Table 2: Frequency distribution of traditional Chinese medicine (TCM) visits by major disease categories (according to 9th ICD codes) in
women with breast cancer from 1999 to 2008 in Taiwan.
Major disease category ICD-9-CM codes
No. of visits N (%)
Chinese herbal remedies Acupuncture and
manipulative therapies Total of TCM
Infectious and parasitic diseases 001–139 44 (0.1) 3 (0.0) 47 (0.2)
Neoplasms 140–239 6,672 (22.5) 1,165 (3.9) 7,837 (26.5)
Breast cancer 174 6,442 (21.7) 1,145 (3.9) 7,587 (25.6)
Other cancers (remainder of
neoplasms) 230 (0.8) 20 (0.1) 250 (0.8)
Endocrine, nutritional and
metabolic diseases, and immunity
disorders
240–279 262 (0.9) 1 (0.0) 263 (0.9)
Mental disorders 290–319 127 (0.4) 9 (0.0) 136 (0.5)
Diseases of the nervous system and
sense organs 320–389 446 (1.5) 69 (0.2) 515 (1.7)
Diseases of the circulatory system 390–459 310 (1.0) 17 (0.1) 327 (1.1)
Diseases of the respiratory system 460–519 3,253 (11.0) 64 (0.2) 3,317 (11.2)
Diseases of the digestive system 520–579 2,222 (7.5) 72 (0.2) 2,294 (7.7)
Diseases of the genitourinary
system 580–629 1,294 (4.4) 74 (0.2) 1,368 (4.6)
Diseases of the skin and
subcutaneous tissue 680–709 366 (1.2) 12 (0.0) 378 (1.3)
Diseases of the musculoskeletal
system and connective tissue 710–739 1,681 (5.7) 2,461 (8.3) 4,142 (14.0)
Symptoms, signs, and ill-deﬁned
conditions 780–799 5,177 (17.5) 108 (0.4) 5,285 (17.8)
Injury and poisoning 800–999 640 (2.2) 2,736 (9.2) 3,376 (11.4)
Supplementary classiﬁcationd V01–V82,
E800–E999 41 (0.1) 59 (0.2) 100 (0.3)
Others∗ 220 (0.7) 23 (0.1) 243 (0.8)
Total 22,755 (76.8) 6,873 (23.2) 29,628 (100)
∗Others include ICD-9-CM codes 280–289, 630–677, 740–759, 760–779 and missing/error data.
dSupplementary classiﬁcation of factors inﬂuencing health status and contact with health service, external causes of injury and poisoning.
with breast cancer was not associated with the use of CHP.
Hence, we inferred that CHP for women with breast cancer
inTaiwanwasgenerallyusedasadjunctstocancertreatment,
rather than as replacements for it.
Previous clinical trials have demonstrated that Jia-wei-
xiao-yao-san (Augmented Rambling Powder), which is the
mostfrequentlyprescribedformulafortreatingbreastcancer
in Taiwan, may be an eﬃcacious therapy for reducing psy-
chological (anxiety and depression) symptoms in postmeno-
pausal women [24]. Among the top 10 most frequently
prescribed formulas for treating breast cancer, Gui-pi-tang
(Ginseng and Longan Combination), Tian-wang-bu-xin-dan
(GinsengandZizyphusCombination),andSuan-zao-ren-tang
(Zizyphus Combination), which all have a long history of
use, are said to nourish the blood and calm the nerves and
are very often prescribed by TCM doctors to alleviate sleep
disturbance [25]. Other commonly prescribed formulas are
often for relieving gastrointestinal discomfort (Ban-xia-xie-
xin-tang,orPinelliaCombination),poorappetite(Xiang-sha-
liu-jun-zi-tang, or Vladimiria and Amomum Combination),
fatigue (Bu-zhong-yi-qi-tang, or Ginseng and Astragalus
Combination),palpitation(Ren-shen-yang-rong-tang,orGin-
seng Nutritive Combination), or swelling of lymph nodes
(San-zhong-kui-jian-tang, or Forsythia and Laminaria Com-
bination). It is apparent from this study that TCM doctors
in Taiwan prescribed herbal therapies mainly for reducing
psychosocial distress and symptomatic discomfort. However,
itremainstobeclariﬁedwhetherfrequentlyprescribedCHPs
containing ren shen (Panax ginseng-radix)a n ddang qui
(Angelicasinensis-radix)forcancertreatmentareintendedby
TCMdoctorstodecreasethetreatment-associatedtoxicityor
to alleviate the cancer-derived symptoms. Notably, there is
yet insuﬃcient evidence for reaching a conclusion regarding
the cost-eﬀectiveness of the simultaneous administration of
cancer treatment with dang qui (Angelica sinensis-radix)o r
ren shen (Panax ginseng Radix)[ 26]. Further studies are
warranted to assess dang qui (Angelica sinensis-radix)o r
ren shen (Panax ginseng Radix) as an add-on treatment for
women receiving conventional breast cancer treatments.
Previous studies revealed that CHP users among women
with breast cancer were more likely to have higher income
or be of younger age [1]. However, the present data6 Evidence-Based Complementary and Alternative Medicine
Table 3: Top 10 herbal formulas prescribed by TCM doctors for treating breast cancer among 503 breast cancer women from 1999 to 2008
in Taiwan.
Herbal formulas English name
Frequency of
prescriptions
N = 6,442 (%)
Average daily dose (g) Average duration for
prescriptions (day)
Jia-wei-xiao-yao-san† Augmented Rambling
Powder 1,045 (16.2) 5.1 12.8
Xiang-sha-liu-jun-zi-tang‡ Vladimiria and
Amomum Combination 450 (7.0) 5.5 11.5
Gui-pi-tang†‡ Ginseng and Longan
Combination 414 (6.4) 5.0 12.1
San-zhong-kui-jian-tang† Forsythia and Laminaria
Combination 367 (5.7) 6.3 10.2
Bu-zhong-yi-qi-tang†‡ Ginseng and Astragalus
Combination 347 (5.4) 5.2 12.3
Tian-wang-bu-xin-dan†‡ Ginseng and Zizyphus
Combination 302 (4.7) 4.7 13.8
Ban-xia-xie-xin-tang‡ Pinellia Combination 289 (4.5) 5.0 11.6
Suan-zao-ren-tang Zizyphus Combination 276 (4.3) 4.5 13.4
Ren-shen-yang-rong-tang†‡ Ginseng Nutritive
Combination 272 (4.2) 5.1 10.3
Xue-fu-zhu-yu-tang† Persica and Achyranthes
Combination 254 (3.9) 3.8 12.2
†Chinese herbal products containing dang qui (Angelica sinensis-radix).
‡Chinese herbal products containing ren shen (Panax ginseng-radix).
demonstratednosigniﬁcantdiﬀerenceinthesetwovariables,
possibly,becausetheNHIsystemhasacomprehensivecover-
ageandthecopaymentforCHPisuniversallyNT$50(appro-
ximately US$1.5), which provides an aﬀordable health access
for all age groups and diﬀerent income levels. Symptoms,
signs, and ill-deﬁned conditions and diseases of the respira-
tory system were the two most frequent diagnoses in disease
category for TCM visits with prescription of CHP, after
breast cancer. The results indicate that, besides breast cancer
care, health care providers should pay more attention to the
general health conditions of patients suﬀering from symp-
toms, signs, and ill-deﬁned conditions as well as respiratory
discomfort and provide proactive recommendations for
these medical needs.
The present study has two limitations. First, because the
identities of the patients were encrypted and thus not avail-
able in the NHI reimbursement database, we were unable
to obtain any histopathology reports to verify the diagnoses.
However, because the registration of breast cancer as a cata-
strophic illness is approved on the basis of pathology and/or
cytology evidence and is followed by a full waiver of copay-
ment, such a diagnosis is made only after very serious review
and is generally accurate. The diagnostic accuracy of breast
canceramongtheNHIdataiscorroboratedbythesigniﬁcant
agreement between the incidence rate calculated herein
and that determined by the National Cancer Registry of
Taiwan, in which 95% of the breast cancers are accompanied
by histopathologic validation. Second, this study did not
include Chinese herbal remedies purchased directly from
TCM herbal pharmacies, nor did we include health food
containing herbs. Thus, the frequency of CHP utilization
might be underestimated. However, because the NHI system
has a comprehensive coverage for TCM prescriptions, which
isgenerallylessthanthecostofherbssoldinTaiwanmarkets,
the likelihood that subjects purchased lots of other herbs
outside the NHI database is not high.
5. Conclusions
It is apparent that our ﬁndings may have implications for
physicians attending to women with breast cancer. Our
results suggest that, under the coexistence of the conven-
tional medical treatments and TCM, most breast cancer
patients consumed herbal therapies with the intention of
relieving their treatment-induced symptoms, rather than
rejecting standard cancer treatments. Recognizing the use of
TCM, exploring potential interactions and adverse eﬀects,
and integrating both technologies may be more beneﬁcial to
the overall health, or survival and quality of life, of breast
cancer patients. Thus, health care providers had better pro-
actively explore a personalized optimal treatment for breast
cancer, as well as attend to the patients’ psychosocial and
physical needs.
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